The Senate on Tuesday began hearings on acting FDA Commissioner Andrew C. von Eschenbach's nomination to head the agency, with a focus on the agency's politicization in the face of the delayed approval for over-the-counter status of Plan B. Von Eschenbach said he is committed to "sound science" and a climate of openness.

Related Summaries